Clinical trial of INZ-701 in children with ABCC6 Deficiency.
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs INZ-701 (Primary)
- Indications Calcinosis
- Focus Adverse reactions
- Sponsors Inozyme Pharma
- 16 Jan 2025 New trial record
- 10 Jan 2025 According to Inozyme Pharma media relase, the company plans to initiate the ASPIRE trial in early 2026.
- 10 Jan 2025 According to Inozyme Pharma media relase, Inozyme is currently refining the study design to harmonize feedback from the FDA and EMA.Also The Company plans to continue regulatory engagement over the coming months to finalize the trial protocol. Pending ongoing regulatory review and the availability of financial resources.